Kalvista Pharmaceuticals (Ireland)

Company snapshot

For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it mos

• 2 approved product(s) across US/EU regulatory metadata.
• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Kalvista Pharmaceuticals (Ireland). Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Kalvista Pharmaceuticals (Ireland).

1. Jun 5, 2026 Clinical update

   Placebo — Phase 3

2. Jun 5, 2026 Clinical update

   KVD824 Prototype 1 modified-release tablet — Phase 1

3. Jun 5, 2026 Clinical update

   KVD001 Injection — Phase 2

4. May 23, 2026 Clinical update

   KVD900 150 mg — Phase 3

5. May 23, 2026 Clinical update

   KVD900 600 mg — Phase 3

View all clinical trial activity →

• What is Kalvista Pharmaceuticals (Ireland)?

  Kalvista Pharmaceuticals (Ireland) is a pharma organization headquartered in Framingham, USA. It trades on NYSE under ticker KALV. Primary therapeutic focus areas include Hereditary Angioedema, Diabetic Macular Edema, Angioedema, Hereditary, Types I and II. NovaPharmaNews links 8

• Is Kalvista Pharmaceuticals (Ireland) publicly traded?

  Yes. Kalvista Pharmaceuticals (Ireland) is listed with ticker KALV on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Kalvista Pharmaceuticals (Ireland) develop or market?

  We link 6 drug profile(s) where Kalvista Pharmaceuticals (Ireland) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kalvista-pharmaceuticals#company-drugs.

• What are the latest developments for Kalvista Pharmaceuticals (Ireland)?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kalvista Pharmaceuticals (Ireland) focus on?

  Kalvista Pharmaceuticals (Ireland) focuses on Hereditary Angioedema, Diabetic Macular Edema, Angioedema, Hereditary, Types I and II based on our analysis of their pipeline programs and drug development activities.